

Parkinson's Disease: Quality Assessment and Improvement of Care

Continuing Medical Education Accreditation

The University of Cincinnati designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)[™]. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Continuing Pharmacy Education Accreditation



Pharmacy Times/Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2.5 contact hours (0.25 CEU) under the ACPE universal program number of 290-999-08-003-H01-P.

Release date: March 31, 2008

Expiration date: March 31, 2009

Instructions

After reading "Parkinson's Disease: Quality Assessment and Improvement of Care," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.

-
- 1. Genetic forms of Parkinson's disease (PD) more frequently appear in:**
 - a. older patients
 - b. young-onset patients
 - c. the majority of patients
 - d. All of the above
 - 2. The most disabling feature of PD is:**
 - a. bradykinesia
 - b. asymmetric rest tremor
 - c. micrographia
 - d. None of the above
 - 3. The most common neuropsychiatric disorder in PD is:**
 - a. dementia
 - b. psychosis (hallucinations and delusional thinking)
 - c. depression
 - d. impulse control disorders

A193

4. **The standard and most commonly used method of assessing motor symptoms and clinical status over time in PD is the:**
 - a. The Scales for Outcomes in Parkinson's Disease (SCOPA)
 - b. Parkinson's Disease Questionnaire-39 (PDQ-39)
 - c. The Parkinson's Impact Scale (PIMS)
 - d. Unified Parkinson's Disease Rating Scale (UPDRS)

5. **The reluctance to start dopaminergic therapy early in disease is because:**
 - a. These agents have adverse effects
 - b. There are long-term consequences of treatment
 - c. Levodopa has been proven to enhance the progression of PD
 - d. a and b

6. **Which statement regarding levodopa therapy is false?**
 - a. With disease progression, the benefits of each dose become shorter, with a wearing off of benefit before the next dose.
 - b. Controlled-release formulations result in predictable onsets of action.
 - c. Virtually all PD patients will require levodopa therapy at some point in their disease.
 - d. Carbidopa is given with levodopa to minimize side effects.

7. **Which statement about treatment with dopamine agonists (DAs) is false?**
 - a. DAs are only used in combination with levodopa.
 - b. Many specialists begin treatment with DAs in younger patients because they are more prone to developing severe motor complications.
 - c. DAs can be used in early PD as monotherapy.
 - d. DAs are more likely to cause cognitive side effects in the elderly than levodopa.

8. **Deep brain stimulation surgery:**
 - a. Is considered the surgical method of choice for patients with advanced disease.
 - b. Should be considered in patients with medically resistant motor fluctuations.
 - c. Has been shown to reduce the primary symptoms of PD and its motor complications.
 - d. All of the above

9. **Risk factors for developing depression in PD include all of the following except:**
 - a. Male sex
 - b. Increasing severity of cognitive impairment
 - c. History of depression before diagnosis of PD
 - d. Early-onset PD

10. **The anxiety disorder in PD that is not seen as commonly as others is:**
 - a. Generalized anxiety disorder
 - b. Panic attacks
 - c. Obsessive-compulsive disorder
 - d. Social anxiety

11. **Which of the sleep disorders occur in PD patients?**
 - a. Daytime hypersomnolence
 - b. Nocturnal insomnia
 - c. Parasomnias
 - d. All of the above

12. **Which of the following statements about dementia in PD is false?**
 - a. Dementia in PD is less common than depression or psychosis.
 - b. Dementia is associated with the underlying neurodegenerative processes in PD.
 - c. Early executive impairment and memory deficits in PD are risk factors for development of dementia.
 - d. PD dementia criteria emphasize the range of cognitive domains that are affected and deemphasize memory impairment.

CME Answer / Evaluation

(PLEASE PRINT CLEARLY)

Name/Degree _____

Street _____

City _____

State/ZIP _____

Daytime Phone _____

Fax _____

E-mail _____

**Sponsored by the University of Cincinnati for
2.5 hours of Category 1 CME credit.**

Release Date: **March 31, 2008**

Expiration Date: **March 31, 2009**

**CME Test Form
Parkinson's Disease:
Quality Assessment and Improvement of Care**

1.	a	b	c	d
2.	a	b	c	d
3.	a	b	c	d
4.	a	b	c	d
5.	a	b	c	d
6.	a	b	c	d
7.	a	b	c	d
8.	a	b	c	d
9.	a	b	c	d
10.	a	b	c	d
11.	a	b	c	d
12.	a	b	c	d

Answer Form Instructions: Testing and Grading Procedures

1. Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CME credits earned. This form should be safeguarded and may be used as documentation of credits earned.
2. Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no cost.
3. All answers should be recorded on the answer form.
4. To receive credit certification electronically, please provide your e-mail address. Detach and mail or fax the test portion of this page to:
University of Cincinnati, Office of CME,
PO Box 670556, Cincinnati, OH 45267-0567; phone: 513-558-7277; fax: 513-558-1708.
Please print clearly to ensure receipt of CME credit.
5. To receive credit and an immediate certificate, register at http://webcentral.uc.edu/cpd_online2/ and complete the test or reader survey. If you have previously registered, enter your user name and password to log in. Otherwise, click **New User? Register!** and complete the registration process (user ID and password will be e-mailed to you immediately). Once you log in, click **CME Text** and scroll down through the course listings to locate this supplement.

CME Activity Evaluation

How long did it take you to complete this activity?

_____ minutes

How well did this activity achieve its educational objectives?

Very well Well Somewhat Not at all

What overall grade would you assign this activity?

A B C D

Did this activity exhibit promotional bias for any pharmaceutical agents?

Yes No

Will you make changes in your practice as a result of information presented in this lesson?

Yes No

A193

**Parkinson's Disease:
Quality Assessment and Improvement of Care**

**(Test valid through March 31, 2009.
No credit will be given after this date.)**

This program is approved for 2.5 contact hours (0.25 CEU) under the ACPE universal program number of 290-999-08-003-H01-P.

1.	a	b	c	d
2.	a	b	c	d
3.	a	b	c	d
4.	a	b	c	d
5.	a	b	c	d
6.	a	b	c	d
7.	a	b	c	d
8.	a	b	c	d
9.	a	b	c	d
10.	a	b	c	d
11.	a	b	c	d
12.	a	b	c	d

- Presently Enrolled in CE Program
- Nonsubscriber Participant Pharmacist

(PLEASE PRINT CLEARLY)

SSN --

Name _____

Address _____

City _____

State _____ Zip _____ Daytime Phone _____

Please mail this form to: PharmacyTimes CE Department, 405 Glenn Drive, Suite 4, Sterling, VA 20164-4432

**Answer Form Instructions:
Testing and Grading Procedures**

1. Each participant achieving a passing grade of 70% or higher on any examination will receive a statement of credit giving the number of CE credits earned. This form should be safeguarded and may be used as documentation of credits earned.
2. Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no extra cost.
3. All answers should be recorded on the answer form. For each question, decide which choice is the best answer, and circle the letter of the response representing your choice.
4. Mail your completed exam form to the following address: PharmacyTimes, CE Department, 405 Glenn Drive, Suite 4, Sterling, VA 20164-4432.

New Scoring Options

1. Mail
2. Fax: 703-404-1801
3. Phone-in: 800-899-6350
(9 AM-5 PM ET, Mon.-Fri.)
4. This lesson is **FREE** online; receive instant grading, and download your certificate—
www.PharmacyTimes.com.

PROGRAM EVALUATION

Please mark your level of agreement with the following statements. (4 = Strongly Agree; 0 = Strongly Disagree)

1) Met its stated objectives	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
1. Review the motor and nonmotor symptoms associated with Parkinson's disease (PD).	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
2. Describe the advantages and disadvantages of the currently available treatment options for PD.	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
3. Identify comorbid conditions commonly associated with PD.	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
2) Work of instructor was high-quality	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
3) Instructional materials were high-quality	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
4) Case studies aided learning	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
5) Presented information in a fairly balanced and noncommercial manner	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
6) Offered information useful in my professional practice	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>
7) Provided new insights into contemporary pharmacy practice	<input type="text" value="4"/>	<input type="text" value="3"/>	<input type="text" value="2"/>	<input type="text" value="1"/>	<input type="text" value="0"/>

A193

